We are live on ! Find out more
GALT icon

Galectin Therapeutics

60 hedge funds and large institutions have $10.5M invested in Galectin Therapeutics in 2023 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 14 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

411% more call options, than puts

Call options by funds: $92K | Put options by funds: $18K

0.15% more ownership

Funds ownership: 12.07%12.22% (+0.15%)

0% more funds holding

Funds holding: 6060 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

29% less capital invested

Capital invested by funds: $14.8M → $10.5M (-$4.35M)

43% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 14

Holders
60
Holders Change
Holders Change %
0%
% of All Funds
0.94%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
3
Increased
8
Reduced
14
Closed
3
Calls
$92K
Puts
$18K
Net Calls
+$74K
Net Calls Change
-$83K

GALT Hedge Fund Activity: Q2 2023 in Review

60 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Galectin Therapeutics (GALT) for Q2 2023, worth a combined $10.5M — down 29% from $14.8M a quarter earlier.

Fund positioning in GALT was balanced in Q2 2023: 3 funds opened new positions, 3 closed out, 8 added to existing stakes and 14 trimmed.

The largest buyer was Osaic Holdings, adding an estimated $278K. The largest seller was Jane Street, exiting entirely with an estimated $85.1K sold.

  • 60 institutional investors held Galectin Therapeutics (GALT) as of Q2 2023, unchanged from Q1 2023.
  • Funds reported $10.5M of Galectin Therapeutics stock for Q2 2023, down 29% quarter-over-quarter.
  • 3 funds opened new Galectin Therapeutics positions in Q2 2023 and 3 closed out, a net change of 0 holders.
  • The largest Galectin Therapeutics buyer in Q2 2023 was Osaic Holdings, an estimated $278K added.
  • The largest Galectin Therapeutics seller in Q2 2023 was Jane Street, an estimated $85.1K sold.

Based on aggregated 13F filings for Q2 2023.